USD10
SPRO Shares
About Spero TherapeuticsSpero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
USD10
SPRO Shares
About Spero TherapeuticsSpero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Stats
TRADING WINDOW
Open
CLOSES AT
8:00 PM GMT+0
MARKET CAP
$132.96M
OPEN PRICE
$2.37
LOW (1Y)
$0.5052
HIGH (1Y)
$3.22
LOW (24H)
$2.33
HIGH (24H)
$2.41
VOLUME (24H)
$52.20K
82.2%
Price history
Time | Price | Change |
|---|---|---|
Today | $2.37 | |
1 Day | $2.29 | |
1 Week | $2.62 | |
1 Month | $2.22 | |
1 Year | $0.8175 |
Discover more
Learn how to buy popular cryptocurrencies
Popular price predictions
Legal
All securities and investments are offered by Coinbase Capital Markets Corp, member FINRA/SIPC. Securities services offered by Coinbase Capital Markets Corp are separate from digital asset services provided by Coinbase Inc., and any affiliates or crypto asset services provided under MiCA by Coinbase Luxembourg S.A. SIPC does not apply to digital assets or cash held in your Coinbase Inc. account. Additional information about your broker, Coinbase Capital Markets Corp, can be found on FINRA’s BrokerCheck. Execution, clearing and custody of all securities are provided by Apex Clearing Corporation.This page and the content herein is for informational purposes only and does not constitute the provision of investment advice. The customer assumes full responsibility for its trading activity and should consult its advisors for its specific situation. This material is not (i) an offer, or solicitation of an offer, to invest in, or to buy or sell, any interests or shares, or to participate in any investment or trading strategy, (ii) intended to provide accounting, legal, or tax advice, or investment recommendations. The information is believed to be current as of the date indicated and may not be updated or otherwise revised to reflect information that subsequently became available or a change in circumstances after the date of publication. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. Recipients should consult their advisors before making any investment decision.All ticker names are trademarks of their respective holders. Any ticker reference does not imply any affiliation with or endorsement by a third party. Real-time quote and/or trade prices are not sourced from all markets, source: Nasdaq Last Sale. Morningstar data ©2026.
